A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Phase 1 Completed 85 enrolled Janssen Research & Development, LLC

NaSequentialOpen-labelTreatment

Summary

The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in Part 2.

Timeline

Start: 2020-07-02
Primary completion: 2025-05-28
Completion: 2025-05-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-64264681	Small molecule	—	Oral

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Summary

Timeline

Drugs

Indications